Tanabe Pharma Corporation
Clinical trials sponsored by Tanabe Pharma Corporation, explained in plain language.
-
New drug trial targets hardening skin in scleroderma patients
Disease control OngoingThis study is testing whether an investigational drug called MT-0551 is better than a placebo at reducing skin thickening in people with systemic sclerosis (scleroderma). The 80 participants will receive either the drug or a placebo for 26 weeks, and researchers will measure chan…
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for Tough-to-Treat blood cancer
Disease control OngoingThis study is testing a new drug called MT-2111 for people with an aggressive type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has returned or hasn't responded to at least two prior treatments. The first part checks the drug's safety and the best dose, while…
Phase: PHASE1, PHASE2 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC